News & Perspective

May 20, 2008

May 20, 2008

FDA approves levofloxacin for anthrax in children

(CIDRAP News) – The US Food and Drug Administration (FDA) recently offered another antibiotic option for combating inhalational anthrax in children by approving the quinolone drug levofloxacin (Levaquin).

In a letter dated May 5, the FDA endorsed the use of levofloxacin, made by Ortho-McNeil, in children 6 months of age and older. The agency had approved use of the drug for postexposure treatment of anthrax in adults in 2004.